SYRE

93.4704.26%
CT

Cameron Turtle

CEO & Director

Dr. Cameron Turtle, D.Phil, Ph.D, joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023 and serves as its Chief Executive Officer and Director at Spyre Therapeutics, Inc Since November 2023. He serves as an Independent Director at Damora Therapeutics, Inc. from March 2026. Dr. Turtle is an experienced leader in building, financing and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization. Dr. Turtle was Independent Director of Oruka Therapeutics, Inc since February 2024 until December 11, 2025. Prior to joining Spyre Therapeutics, Inc, Dr. Turtle was an advisor to Pre-Merger Spyre from May 2023 to June 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology company, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November 2018 to January 2021, where he led business development, Investor Relations and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey & Company, where he worked with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy and sales force optimization. Dr. Turtle received his B. S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John’s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30, San Francisco Business Times 40 Under 40 and the Biocom Life Sciences Catalyst Award.

Positions